René S Kahn, MD, PhD Email René Kahn
- SYSTEM CHAIR, DEPARTMENT OF PSYCHIATRY
- PROFESSOR | Psychiatry
- Hospital Affiliations
- Mount Sinai St. Luke's and Mount Sinai West
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
Dr René Kahn is the Esther and Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai. After completing Medical School in the Netherlands (1979) and having actively served in the 42 Armd Brigade of the Royal Army of the Netherlands as a 1st Lt (he retired a Lt. Col in the Army Reserve), he was trained as a psychiatrist and neurologist in Utrecht and Amsterdam, respectively. He then moved to New York City (1985), where he did a research fellowship in biological psychiatry at Albert Einstein College of Medicine. He subsequently completed his psychiatry residencies at Mount Sinai Hospital and then worked as Chief of the psychiatry research unit at the Bronx VA. In 1993 he moved back to Utrecht to become to Chair of Psychiatry at the University hospital, going on to lead the Brain Center Rudolf Magnus, which combines research in basic neuroscience, psychiatry and neurology. He remained connected to Mount Sinai School of Medicine as an Adjunct Associate professor for several years.
One of his most important contributions to science has been to help provide the scientific foundation of the century-old postulate that schizophrenia debuts with cognitive dysfunction - preceding the onset of the first psychosis by more than a decade. Moreover, he and his group have shown that brain changes in schizophrenia are progressive over time; and that these changes are clinically relevant, related as they are to outcome and to loss of cognitive function during the course of the illness. Finally, his research has shown that brain volume is one of the most heritable characteristics of man, paving the way to link brain volumes in health and disease to genetic variation. During his time in Europe he initiated several large treatment trials in schizophrenia in order to improve the outcome of patients with schizophrenia. He is also involved in many other collaborative studies, examining both genetic and neuroimaging parameters. His work has been funded by various sources such as the European Union, the Dutch Government, NIMH and the Stanley Foundation.
Dr Kahn has published over 800 research papers and in 2015 and 2016 was named Thomson Reuters’ highly cited researcher, representing ‘some of the world’s most influential scientific minds’. He has served on neuroscience grant review boards in the Netherlands as well as those of the United Kingdom and Germany. He received several honors, such as a Fulbright Scholarship, membership of the Royal Netherlands Academy of Arts and Sciences, the ECNP Neuropsychopharmacology Award, an honorary doctorate at Semmelweis University in Budapest, Hungary and the lifetime achievement award of the Netherlands Psychiatric Association. He is Honorary Lifetime Professor at Jilin University in Changchun, China. He was Treasurer and Vice-President of the European College of Neuropsychopharmacology and is currently past-President of The Schizophrenia International Research Society. He is a fellow of the American College of Neuropsychopharmacology.
School of Medicine, University Groningen, The Netherlands 1972-1979
Psychiatry residencies, University Hospital Utrecht, The Netherlands 1981-1983
Neurology residencies, Academic Medical Center, Amsterdam, The Netherlands 1983-1985
Fellowship Biological Psychiatry, Montefiore Hospital and Albert Einstein College of Medicine, New York, U.S.A. 1985-1988
Residencies Psychiatry, Mount Sinai Hospital/Bronx VA Medical Center,, New York, U.S.A. 1988-1992
MD/PHD, Groningen Medical School
Mount Sinai Hospital
Lifetime Achievement Award, Netherlands Association of Psychiatry
Netherlands Association of Psychiatry
Neuropsychopharmacology Award, ECNP
Honorary Doctorate, Semmelweis University, Budapest, Hungary
Semmelweis University, Budapest, Hungary
Honorary Professor, Jilin University, People's Republic of China
Jilin University, Peoples Republic of China
Member, Royal Netherlands Academy for Arts and Science
Royal Netherlands Academy for Arts and Science
Ramaer Medal, Netherlands Association of Psychiatry
Netherlands Association of Psychiatry
Vink M, Ramsey NF, Raemaekers M, Kahn RS. Striatal dysfunction in schizophrenia and unaffected relatives. Biological psychiatry 2006 Jul; 60(1).
Cahn W, van Haren NE, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DA, Kahn RS. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. The British journal of psychiatry : the journal of mental science 2006 Oct; 189.
Boos HB, Aleman A, Cahn W, Hulshoff Pol H, Kahn RS. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Archives of general psychiatry 2007 Mar; 64(3).
van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Brans R, Carati I, Rais M, Kahn RS. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biological psychiatry 2008 Jan; 63(1).
Aukes MF, Alizadeh BZ, Sitskoorn MM, Selten JP, Sinke RJ, Kemner C, Ophoff RA, Kahn RS. Finding suitable phenotypes for genetic studies of schizophrenia: heritability and segregation analysis. Biological psychiatry 2008 Jul; 64(2).
Sommer IE, Diederen KM, Blom JD, Willems A, Kushan L, Slotema K, Boks MP, Daalman K, Hoek HW, Neggers SF, Kahn RS. Auditory verbal hallucinations predominantly activate the right inferior frontal area. Brain : a journal of neurology 2008 Dec; 131(Pt 12).
van der Schot AC, Vonk R, Brans RG, van Haren NE, Koolschijn PC, Nuboer V, Schnack HG, van Baal GC, Boomsma DI, Nolen WA, Hulshoff Pol HE, Kahn RS. Influence of genes and environment on brain volumes in twin pairs concordant and discordant for bipolar disorder. Archives of general psychiatry 2009 Feb; 66(2).
Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). The American journal of psychiatry 2009 Jun; 166(6).
van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L, Evans AC, Hulshoff Pol HE, Kahn RS. Changes in cortical thickness during the course of illness in schizophrenia. Archives of general psychiatry 2011 Sep; 68(9).
Hulshoff Pol HE, van Baal GC, Schnack HG, Brans RG, van der Schot AC, Brouwer RM, van Haren NE, Lepage C, Collins DL, Evans AC, Boomsma DI, Nolen W, Kahn RS. Overlapping and segregating structural brain abnormalities in twins with schizophrenia or bipolar disorder. Archives of general psychiatry 2012 Apr; 69(4).
van den Heuvel MP, Kahn RS, Goñi J, Sporns O. High-cost, high-capacity backbone for global brain communication. Proceedings of the National Academy of Sciences of the United States of America 2012 Jul; 109(28).
Geyer MA, Olivier B, Joëls M, Kahn RS. From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends in pharmacological sciences 2012 Oct; 33(10).
Terwisscha van Scheltinga AF, Bakker SC, van Haren NE, Derks EM, Buizer-Voskamp JE, Boos HB, Cahn W, Hulshoff Pol HE, Ripke S, Ophoff RA, Kahn RS. Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. Biological psychiatry 2013 Mar; 73(6).
van den Heuvel MP, Sporns O, Collin G, Scheewe T, Mandl RC, Cahn W, Goñi J, Hulshoff Pol HE, Kahn RS. Abnormal rich club organization and functional brain dynamics in schizophrenia. JAMA psychiatry 2013 Aug; 70(8).
Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA psychiatry 2013 Oct; 70(10).
Kubota M, van Haren NE, Haijma SV, Schnack HG, Cahn W, Hulshoff Pol HE, Kahn RS. Association of IQ Changes and Progressive Brain Changes in Patients With Schizophrenia. JAMA psychiatry 2015 Aug; 72(8).
van den Heuvel MP, Scholtens LH, de Reus MA, Kahn RS. Associated Microscale Spine Density and Macroscale Connectivity Disruptions in Schizophrenia. Biological psychiatry 2016 Aug; 80(4).
Toulopoulou T, van Haren N, Zhang X, Sham PC, Cherny SS, Campbell DD, Picchioni M, Murray R, Boomsma DI, Hulshoff Pol HE, Pol HH, Brouwer R, Schnack H, Fañanás L, Sauer H, Nenadic I, Weisbrod M, Cannon TD, Kahn RS. Reciprocal causation models of cognitive vs volumetric cerebral intermediate phenotypes for schizophrenia in a pan-European twin cohort. Molecular psychiatry 2015 Nov; 20(11).
Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, O'Donovan M, Correll CU, Kane JM, van Os J, Insel TR. Schizophrenia. Nature reviews. Disease primers 2015 11; 1.
Schnack HG, van Haren NE, Nieuwenhuis M, Hulshoff Pol HE, Cahn W, Kahn RS. Accelerated Brain Aging in Schizophrenia: A Longitudinal Pattern Recognition Study. The American journal of psychiatry 2016 Jun; 173(6).
Koutsouleris N, Kahn RS, Chekroud AM, Leucht S, Falkai P, Wobrock T, Derks EM, Fleischhacker WW, Hasan A. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. The lancet. Psychiatry 2016 Oct; 3(10).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Kahn did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.